Clinical Trial - Autologous Peripheral Blood Stem Cell (PBSC) Transplantation Followed By Non-Myeloablative Allogeneic PBSC Transplantation in Patients With Multiple Myeloma

Title:	Autologous Peripheral Blood Stem Cell (PBSC) Transplantation Followed By Non-Myeloablative Allogeneic PBSC Transplantation in Patients With Multiple Myeloma

Phase:	II

Purpose:	This trial will couple an autologous transplant with multiple myeloma with a subsequent non-myeloablative sibling transplant in order to assess the feasibility of this approach and whether graft-versus-myeloma can improve disease-free survival.

Eligibility:	The eligibility criteria include the following: Patients must have active multiple myeloma requiring treatment No more than 12 months of prior alkylating-agent therapy No more than 18 months of all prior therapy No more than one prior progression after intial therapy Greater than 4 weeks since prior treatment Identification of an HLA-identical sibling donor Age less than 65 years Performance status of 0-1 DLCO greater than 40% LVEF greater than 30% No uncontrolled diabetes mellitus or active serious infection Other criteria will be evaluated upon consultation.

Contact:	Beth Kaufman, RN University of Iowa Hospitals & Clinics 319-384-9562

Please note: the trials indicated do not include the full inclusion or exclusion criteria. For full protocols, please contact the Principal Investigator (PI) listed.